Tresiba and Lung disorder - a phase IV clinical study of FDA data

Summary:

Lung disorder is reported as a side effect among people who take Tresiba (insulin degludec), especially for people who are female, 60+ old, also take Humalog, and have Diabetes.

The phase IV clinical study analyzes which people have Lung disorder when taking Tresiba. It is created by eHealthMe based on reports of 20,507 people who have side effects when taking Tresiba from the FDA, and is updated regularly.

What is Tresiba?

Tresiba has active ingredients of insulin degludec. It is often used in type 1 diabetes. eHealthMe is studying from 20,677 Tresiba users. Check the latest studies of Tresiba.

What is Lung disorder?

Lung disorder (lung disease) is found to be associated with 1,805 drugs and 1,785 conditions by eHealthMe. Check the latest studies of Lung disorder.

On Jul, 11, 2026

20,507 people reported to have side effects when taking Tresiba.
Among them, 30 people (0.15%) have Lung disorder.

Among these 30 people:

What is the gender of people who have Lung disorder when taking Tresiba? *

female: 56 %
male: 44 %

What is the age of people who have Lung disorder when taking Tresiba? *

What are other drugs people take besides Tresiba? *

What are other side effects people have besides Lung disorder? *

Fatigue (feeling of tiredness): 7 people, 23.33%
High Blood Pressure: 5 people, 16.67%
Dyspnea (difficult or laboured breathing): 5 people, 16.67%
Fall: 5 people, 16.67%
Joint Pain: 5 people, 16.67%
Weakness: 5 people, 16.67%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 4 people, 13.33%
Back Pain: 4 people, 13.33%
Pain: 4 people, 13.33%
Hypoglycemia (low blood sugar): 4 people, 13.33%

What are the existing conditions these people have? *

Diabetes: 5 people, 16.67%
Type 2 Diabetes: 3 people, 10.00%
Immunodeficiency Common Variable: 3 people, 10.00%
Thrombocytopenia (decrease of platelets in blood): 3 people, 10.00%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 3 people, 10.00%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 3 people, 10.00%
Lymphocytic Leukaemia (a type of cancer in which the bone marrow makes too many lymphocytes): 3 people, 10.00%
Immunodeficiency: 3 people, 10.00%
Cystic Fibrosis (disease of the secretary glands): 2 people, 6.67%
Dyslipidaemia (abnormal amount of lipids): 2 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Tresiba and have Lung disorder?

- Check whether Lung disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tresiba:

Tresiba (20,677 reports)

Lung disorder treatments and more:

Lung disorder (66,567 reports)

Browse all side effects of Tresiba:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Lung disorder:

Lung disorder (1,805 drugs)

Browse all the conditions that are associated with Lung disorder:

Lung disorder (1,785 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on insulin degludec (the active ingredients of Tresiba) and Tresiba (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.